Healthcare Business - Page 2

Short Sellers Run for Cover From Major Pharma Stocks

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Analysts Keep Stacking Up Higher Targets and Expectations for Eli Lilly

Eli Lilly and Co. (NYSE: LLY) is one of the better pharmaceutical stocks, as far as performers in 2017 top picks at JPMorgan. Its shares were last seen up 17% ...
Read Full Story »

Why Jefferies Still Sees Exponential Upside in TherapeuticsMD

TherapeuticsMD Inc. (NYSEMKT: TXMD) saw its shares drop off earlier this month after the company received a letter from the U.S. Food and Drug Administration (FDA) citing deficiencies in its ...
Read Full Story »

Akcea Therapeutics Gears Up for IPO

Akcea Therapeutics has filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO). The only pricing detail listed in the filing ...
Read Full Story »

Cytori Rises on Crucial FDA Approval

Cytori Therapeutics Inc. (NASDAQ: CYTX) saw its shares explode after it was reported that the firm received approval from the U.S. Food and Drug Administration (FDA) for its treatment of ...
Read Full Story »

OncoMed Hits All-Time Low After Failed Trial and Licensing Fallout

OncoMed Pharmaceuticals Inc. (NASDAQ: OMED) saw its shares crumble after the company announced that Bayer Pharma is terminating its option agreement with the company, as well as a missed mid-stage ...
Read Full Story »

Jefferies Thinks 3 Red-Hot Biotech Stocks Can Beat Q1 Estimates

If any industry has been under pressure over the past year or so, it has been biotechnology. While there are some positives for the industry, it still faces some definite ...
Read Full Story »

Biohaven Files for IPO

Biohaven Pharmaceutical Holding has filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). No pricing details were listed in the filing but ...
Read Full Story »

Catalyst Biosciences Sinks After Pricing Secondary Offering

Catalyst Biosciences Inc. (NASDAQ: CBIO) watched its shares fall on Friday following the announcement of a secondary offering. The company is focused on treatments in the field of hematology and ...
Read Full Story »

Aurinia Pharmaceuticals Jumps on Phase 3 Planned Trial

Shares of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) saw a handy gain on Friday after the company announced plans for the development of a late-stage trial. Specifically, Aurinia conducted discussions with ...
Read Full Story »

Neothetics Posts Solid Win on Patent Approval

Neothetics Inc. (NASDAQ: NEOT) saw its stock hit a multiyear high on Wednesday after the firm announced a critical patent approval. The U.S. Patent and Trademark Office (USPTO) issued U.S. ...
Read Full Story »

Is This the Turnaround Paratek Has Been Looking For?

Shares of Paratek Pharmaceuticals Inc. (NASDAQ: PRTK) saw a huge gain early on Tuesday after the company provided a critical update on its late-stage pneumonia trial. Specifically, the firm reported ...
Read Full Story »

Fresh Off IPO, Therapix Biosciences Already Aiming at Tourette’s Phase 3 Trial

The road to a pivotal Phase 3 trial usually takes years following an initial public offering, but Therapix Biosciences Ltd. (NASDAQ: TRPX) may reach that stage in just a few ...
Read Full Story »

Why One Analyst Sees Almost 40% Upside in Integra LifeSciences

Integra LifeSciences Holdings Corp. (NASDAQ: IART) has not reacted to a very positive analyst call, but this is also a call that falls outside of most analyst screens. Argus reiterated ...
Read Full Story »

Tocagen Announces Potential Pricing for IPO

Tocagen has filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) in relation to its initial public offering (IPO). The company expects to price its 7.25 ...
Read Full Story »